Despite the establishment of cGAS-STING as a critical ferroptosis regulator, key questions remain unresolved, including the context-dependent molecular switches that determine whether pathway activation promotes ferroptosis versus other outcomes (e.g., inflammation and senescence) across cancer types and the influence of chronic versus acute STING activation on therapeutic efficacy and resistance. The gene discussed is CGAS; the disease is cancer.